Finch Therapeutics Group, Inc. (FNCHQ): Nasdaq/NYSE listing notice — Finch Therapeutics receives Nasdaq deficiency notice for bid price below $1.00

Finch Therapeutics Group, Inc.

Received Nasdaq deficiency letter on Dec 30, 2022 for non-compliance with $1.00 minimum bid price requirement.
Has 180 calendar days (until June 28, 2023) to regain compliance by closing at $1.00+ for 10 consecutive days.
May be eligible for additional 180-day extension if it transfers listing to Nasdaq Capital Market.
Company may consider a reverse stock split to regain compliance, subject to board and shareholder approval.
No assurance compliance will be regained; failure could lead to delisting.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Finch Therapeutics Group, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

December 30, 2022, Finch Therapeutics Group, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $ 0.001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The deficiency letter has no immediate effect on the

View on SEC.gov

Browse all listing & compliance notices →

Finch Therapeutics Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-000285

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.